Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACI-19764 in Healthy Participants and Participants With Cardiovascular Risk Factors
NCT07463196Phase 1Recruiting
- Sponsor
- AC Immune SA
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACI-19764 in obesity and type 2 diabetes mellitus (T2DM) (13 arms), sponsored by AC Immune SA. Primary endpoints: Frequency of Adverse Events and Serious Adverse Events, Change from baseline in blood pressure and 7 more. Started Jan 2026; status: recruiting.
02
Drugs
ACI-19764
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07463196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463196.